Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Hellenic Dynamics SA on Thursday reported a widened half-year loss, though it hailed
a period of ‘significant strategic progress’.
In the six months to September 30, its pretax loss widened to £956,782 from £167,768 year-on-year, the cultivator and supplier of medical cannabis products said. Hellenic operates a facility in northern Greece.
Hellenic posted no revenue for the six month period, unchanged from a year prior.
However, over the six months, Hellenic signed a number of partnerships which may strengthen its position as one of Europe’s leading medical cannabis suppliers.
Hellenic received a European Union grant of €304,425 through the EU’s Horizon Europe research funding project.
The company also entered into a five-year pact with Elgo-Dimitra, a public sector entity of the Greek Ministry of Agriculture, Development & Food. The deal sets out the intention to collaborate on research and registration of medical cannabis genetics for European intellectual property ownership.
Hellenic entered into another five-year deal with the University of Patras in Greece to develop joint scientific research projects, with the intention to focus on cannabis-based molecules for use in clinical trials.
The company signed a pact with Demecan Holdings, a German medical cannabis producer, for the cultivation and supply of medical cannabis flowers.
Chief Executive Officer Davinder Rai said: ‘The interim period and post period has been one of significant strategic progress, culminating in the completion of what I truly believe to be one of the most sophisticated cultivation facilities in Europe or even further.’
Hellenic shares were up 9.9% at 3.76 pence each in London on Thursday afternoon.
Copyright 2023 Alliance News Ltd. All Rights Reserved.